Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1 , Pages 49-60 , January 2008

Behavioral effects of current Alzheimer’s disease treatments: A descriptive review

  • Jeffrey L. Cummings

      Affiliations

    • UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    • Corresponding Author InformationCorresponding author. Tel.: 310-794-3665; fax: 310-794-3148.
    • ,
  • Joan Mackell

      Affiliations

    • Pfizer Inc, New York, NY, USA
    • ,
  • Daniel Kaufer

      Affiliations

    • Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

References 

  1. Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 2005;13:460–468
  2. Cummings JL. The neuropsychiatric burden of neurological diseases in the elderly. Int Psychogeriatr. 2005;17:341–351
  3. Hollingworth P, Hamshere ML, Moskvina V, Dowzell K, Moore PJ, Foy C, et al. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer’s disease. J Am Geriatr Soc. 2006;54:1348–1354
  4. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2003;15:346–353
  5. Piccininni M, Di Carlo A, Baldereschi M, Zaccara G, Inzitari D. Behavioral and psychological symptoms in Alzheimer’s disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord. 2005;19:276–281
  6. Steffens DC, Maytan M, Helms MJ, Plassman BL. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimer’s Dis Other Demen. 2005;20:367–373
  7. Suh GH, Kim SK. Behavioral and Psychological Signs and Symptoms of Dementia (BPSD) in antipsychotic-naive Alzheimer’s disease patients. Int Psychogeriatr. 2004;16:337–350
  8. Black W, Almeida OP. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Psychogeriatr. 2004;16:295–315
  9. Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16:248–253
  10. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59:1721–1729
  11. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17:403–408
  12. Phillips VL, Diwan S. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. J Am Geriatr Soc. 2003;51:188–193
  13. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. J Am Med Assoc. 2002;287:2090–2097
  14. Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:469–474
  15. Conwell Y, Pearson J, DeRenzo EG. Indirect self-destructive behavior among elderly patients in nursing homes: a research agenda. Am J Geriatr Psychiatry. 1996;4:152–163
  16. Boustani M, Zimmerman S, Williams CS, Gruber-Baldini AL, Watson L, Reed PS, et al. Characteristics associated with behavioral symptoms related to dementia in long-term care residents. Gerontologist. 2005;45:56–61
  17. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller H-J, et al. The effects of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237–244
  18. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57:613–620
  19. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488
  20. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease: Donepezil Study Group. Neurology. 1998;50:136–145
  21. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61:1852–1856
  22. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489–495
  23. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057–1065
  24. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14:704–715
  25. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341
  26. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology. 2000;54:2269–2276
  27. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4–15
  28. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605–612
  29. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease. Curr Med Res Opin. 2002;18:347–354
  30. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214–219
  31. Mega MS, Masterman DM, O’Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56:1388–1393
  32. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;17:100–108
  33. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57–63
  34. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161:532–538
  35. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3:137–148
  36. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr Med Res Opin. 2004;20:1605–1612
  37. Hatoum HT, Lin SJ, Arcona S, Thomas SK, Koumaras B, Mirski D. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer’s disease. J Am Med Dir Assoc. 2005;6:238–245
  38. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20:559–569
  39. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590–1599
  40. Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs. 2006;20:311–325
  41. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–2115
  42. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71:589–595
  43. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20:120–132
  44. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc. 2004;291:317–324
  45. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  46. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” (A practical method for grading the cognitive state of patients for the clinician). J Psychiatr Res. 1975;12:189–198
  47. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20:459–464
  48. Matthews HP, Korbey J, Wilkinson DG, Rowden J. Donepezil in Alzheimer’s disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry. 2000;15:713–720
  49. Tanaka M, Namiki C, Thuy DH, Yoshida H, Kawasaki K, Hashikawa K, et al. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer’s disease. J Neurol Sci. 2004;225:135–141
  50. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer’s disease. Clin Neuropharmacol. 2002;25:313–317
  51. Barak Y, Bodner E, Zemishlani H, Mirecki I, Aizenberg D. Donepezil for the treatment of behavioral disturbances in Alzheimer’s disease: a 6-month open trial. Arch Gerontol Geriatr. 2001;33:237–241
  52. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA. Effects of donepezil on emotional/behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry. 2000;61:487–492
  53. Patterson CE, Passmore AP, Crawford VL. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer’s disease. Int J Clin Pract. 2004;58:144–148
  54. Monsch AU, Giannakopoulos P. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer’s disease. Curr Med Res Opin. 2004;20:931–938
  55. Brodaty H, Woodward M, Boundy K, Barnes N, Allen G. A naturalistic study of galantamine for Alzheimer’s disease. CNS Drugs. 2006;20:935–943
  56. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract. 2006;60:110–118
  57. Frankfort SV, Appels BA, De Boer A, Tulner LR, Van Campen JP, Koks CH, et al. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer’s disease in an outpatient geriatric setting. Int J Clin Pract. 2006;60:646–654
  58. Gauthier S, Juby A, Morelli L, Rehel B, Schecter R. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin. 2006;22:2251–2265
  59. Dautzenberg PL, Wouters CJ, Bootsma JE. Observations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of AD. Int Psychogeriatr. 2006;18:179–181
  60. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin. 2005;21:1317–1327
  61. Wood S, Cummings JL, Hsu M-A, Barclay T, Wheatley MV, Yarema KT, et al. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry. 2000;8:75–83
  62. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135–146
  63. Hope T, Keene J, Fairburn C, McShane R, Jacoby R. Behaviour changes in dementia (2: are there behavioural syndromes?). Int J Geriatr Psychiatry. 1997;12:1074–1078
  64. Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer’s disease. Int J Geriatr Psychiatry. 2001;16:1037–1042
  65. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043–1053
  66. Robert PH, Verhey FR, Byrne EJ, Hurt C, De Deyn PP, Nobili F, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects—consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20:490–496
  67. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol. 1996;9:1–6

PII: S1552-5260(07)00622-X

doi: 10.1016/j.jalz.2007.10.011

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1 , Pages 49-60 , January 2008

Article Tools